MedTrace Logo

Pharmacological Treatment of Children and Adolescents With Severe Mood Dysregulation

NCT00825552 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2009-01-21

No results posted yet for this study

Summary

The purpose of this study is to investigate whether Risperidone is effective in children and adolescents with severe mood dysregulation.

Conditions

  • Severe Mood Dysregulation

Interventions

DRUG

Risperidone

0,5-4 mg/day for 8 weeks (twice a day)

Sponsors & Collaborators

  • Federal University of Rio Grande do Sul

    lead OTHER

Principal Investigators

  • Rohde A Luis, Phd · Federal University of Rio Grande do Sul

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
7 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2010-01-31
Completion
2010-11-30

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00825552 on ClinicalTrials.gov